In seinem Fachbeitrag stellt Dr. Thomas Prexl neue Ideen für die Weiterentwicklung der Startfinanzierung im Biotech-Bereich vor: Die Biotech-Szene in Deutschland wächst kontinuierlich, dennoch bleibt die Finanzierung klinischer Studien eine anspruchsvolle Aufgabe. Deshalb setzen Heidelberg und die Rhein-Neckar-Region einen neuen Schwerpunkt auf die Frühphasenfinanzierung translationaler Forschung. Wie eine solche Finanzierung aussehen kann?
Lesen Sie den gesamten Artikel. Dem Wunsch nach Internationalität in Biotech- und Finanzwelt entsprechend sowie angelehnt an die Sprache beim Biotech Investors Day am Montag, 8. April 2019, erscheint diese Ausgabe in Englisch.
Das ganze Heft können Sie hier als PDF herunterladen!
In der englischsprachigen Fachzeitschrift finden Sie folgende Inhalte:
- Editorial Dare! Introduction 6 Invest in Biotech! Challenges and opportunities (Page 3)
- Venture capital and the capital market are key The German biotech industry and its policies – challenges and possible solutions (Page 10)
- “When it comes to drugs, artificial intelligence is highly interesting” Tech Talk – Interview with Dr Werner Lanthaler, Evotec (Page 14)
- “The English language is an integral part of capital market communication” Interview with Marlen Schrader, Member of the Management Board and Chief Sales Officer, EnglishBusiness Legal (Page 16)
- Chinese investments in the European biotechnology sector Overcoming challenges in cross-border collaborations Peter Homberg, Dentons (Page 18)
- A full spectrum of options Managing your patent portfolio to satisfy investors’ expectations Dr Andrea Schüßler, Huber & Schuessler Case Study (Page 20)
- Added benefits through combinability Vira Therapeutics GmbH: Immunotherapy for cancer treatment (Page 22)
- Who is Who in Life Sciences 3 industry players introduce themselves Financing (Page 24)
- “The convergence of biotech and big data will have a strong impact on medicine” Interview with Dr Holger Reithinger, Forbion (Page 26)
- New Visions! In North Rhine-Westphalia, business angels are playing an increasingly important role in financing biotech start-ups (Page 28)
- Beyond Imagination Exploring the value that M Ventures brings to the start-up ecosystem Therese Liechtenstein, PhD, M Ventures (Page 30)
- New funding concepts for translational projects Heidelberg and the RhineNeckar region are working on new ideas for biotech startup funding Dr Thomas Prexl, Heidelberg Startup Partners (Page 32)
- “Risks and decisions are more readily taken, generally speaking” Interview with Dr Alexander Schuth, Denali Therapeutics Capital Market & Investment (Page 34)
- Another record year for US Biotech IPOs When will Europe join the party? Dr Marcus Wieprecht, MainFirst Bank (Page 36)
- “The topic of IPOs is and will remain an interesting option for financing company growth” Interview with Sebastian Grabert, Euronext (Page 38)
- Headwinds in European healthcare? Silicon Valley Bank’s Nooman Haque on the 2019 outlook for Life Science Nooman Haque, Silicon Valley Bank’s UK Branch Service 42 Partners’ portraits (Page 40)
- Event calendar (Page 44)
Wir wünschen Ihnen viel Freunde beim Lesen!
